[8-K] Carlisle Companies, Inc. Reports Material Event
Medtronic plc (MDT) 鈥� Form 4 insider filing. On 07/28/2025 the company granted equity awards to Harry Skip Kiil, EVP & President Cardiovascular. The filing shows no open-market trades; all transactions carry code 鈥淎鈥� (award).
- Restricted Stock Units: 7,612 ordinary shares, vest 100% on the third anniversary. Beneficial ownership of ordinary shares rises to 41,318.
- Performance Share Units (PSUs): Target 19,028 shares (0鈥�38,056 range) contingent on 3-year performance metrics concluding 04/28/2028.
- Stock Options: 53,671 options with a $91.97 strike, expiring 07/28/2035; 25% become exercisable each year starting 07/28/2026.
After the grants the insider directly holds 41,318 ordinary shares plus 19,028 PSUs and 53,671 options. The awards represent standard annual long-term incentive compensation meant to align management with shareholders and encourage retention. Given MDT鈥檚 ~1.3 bn share count, the dilution impact is immaterial (<0.01%). No sales were reported, so trading sentiment cannot be inferred.
Medtronic plc (MDT) 鈥� Comunicazione interna Form 4. Il 28/07/2025 la societ脿 ha assegnato premi azionari a Harry Skip Kiil, EVP e Presidente Cardiovascolare. La comunicazione non evidenzia operazioni sul mercato aperto; tutte le transazioni sono classificate con il codice 鈥淎鈥� (assegnazione).
- Azioni vincolate (Restricted Stock Units): 7.612 azioni ordinarie, con maturazione completa al terzo anniversario. La propriet脿 effettiva delle azioni ordinarie sale a 41.318.
- Azioni a prestazione (Performance Share Units - PSU): Obiettivo di 19.028 azioni (intervallo 0鈥�38.056) subordinato al raggiungimento di metriche di performance triennali con scadenza 28/04/2028.
- Opzioni su azioni: 53.671 opzioni con prezzo di esercizio di 91,97$, in scadenza il 28/07/2035; il 25% diventa esercitabile ogni anno a partire dal 28/07/2026.
Dopo queste assegnazioni, l鈥檌nsider detiene direttamente 41.318 azioni ordinarie, oltre a 19.028 PSU e 53.671 opzioni. I premi rappresentano una normale forma di compenso incentivante a lungo termine, finalizzata ad allineare il management con gli azionisti e favorire la retention. Considerando il capitale sociale di MDT di circa 1,3 miliardi di azioni, l鈥檌mpatto diluitivo 猫 trascurabile (<0,01%). Non sono state riportate vendite, quindi non 猫 possibile dedurre il sentiment di trading.
Medtronic plc (MDT) 鈥� Presentaci贸n interna Formulario 4. El 28/07/2025 la empresa otorg贸 premios accionariales a Harry Skip Kiil, EVP y Presidente de Cardiovascular. La presentaci贸n no muestra operaciones en mercado abierto; todas las transacciones llevan el c贸digo 鈥淎鈥� (adjudicaci贸n).
- Unidades de acciones restringidas (RSUs): 7.612 acciones ordinarias, que se consolidan al 100% en el tercer aniversario. La propiedad efectiva de acciones ordinarias aumenta a 41.318.
- Unidades de acciones por desempe帽o (PSUs): Objetivo de 19.028 acciones (rango 0鈥�38.056) condicionado a m茅tricas de desempe帽o a 3 a帽os que concluyen el 28/04/2028.
- Opciones sobre acciones: 53.671 opciones con precio de ejercicio de $91,97, expiran el 28/07/2035; el 25% se vuelve ejercitable cada a帽o a partir del 28/07/2026.
Tras las concesiones, el insider posee directamente 41.318 acciones ordinarias, m谩s 19.028 PSUs y 53.671 opciones. Los premios representan una compensaci贸n est谩ndar anual a largo plazo destinada a alinear la gesti贸n con los accionistas y fomentar la retenci贸n. Dado que MDT tiene aproximadamente 1,3 mil millones de acciones en circulaci贸n, el impacto dilutivo es insignificante (<0.01%). No se reportaron ventas, por lo que no se puede inferir el sentimiento de negociaci贸n.
Medtronic plc (MDT) 鈥� 雮措秬鞛� Form 4 鞁犼碃. 2025雲� 7鞗� 28鞚� 須岇偓電� 鞁槇甏� 攵�氍� EVP 瓴� 靷灔鞚� Harry Skip Kiil鞐愱矊 欤检嫕 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 鞁犼碃靹滌棎電� 鞁滌灔 雮� 瓯半灅 鞐嗢潓鞚� 氇呾嫓霅橃柎 鞛堨溂氅�, 氇摖 瓯半灅電� 旖旊摐 鈥淎鈥�(靾橃棳)搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
- 鞝滍暅 欤检嫕 雼渼(RSUs): 7,612 氤错喌欤�, 3欤茧厔 旮半厫鞚检棎 100% 氩犾姢韺�. 氤挫湢 欤检嫕 靾橂姅 41,318欤茧 歃濌皜頃╇媹雼�.
- 靹标臣 欤检嫕 雼渼(PSUs): 氇╉憸 19,028欤� (0~38,056 氩旍渼), 3雲� 靹标臣 歆�響滌棎 霐半澕 2028雲� 4鞗� 28鞚检棎 斓滌 韽夑皜.
- 鞀ろ啞 鞓奠厴: 頄夓偓臧� 91.97雼煬鞚� 53,671欤�, 毵岅赴 2035雲� 7鞗� 28鞚�; 2026雲� 7鞗� 28鞚茧秬韯� 毵る厔 25%鞌� 頄夓偓 臧�電�.
鞚措矆 攵�鞐� 頉� 雮措秬鞛愲姅 歆侅爲 41,318欤� 氤错喌欤检檧 19,028 PSUs, 53,671 鞀ろ啞 鞓奠厴鞚� 氤挫湢頃橁矊 霅╇媹雼�. 鞚� 氤挫儊鞚� 瓴届榿歆勱臣 欤检＜ 臧� 鞚错暣毳� 毵烄稊瓿� 鞚胳灛 鞙犾毳� 鞛ル牑頃橁赴 鞙勴暅 響滌 鞐瓣皠 鞛リ赴 鞚胳劶韹半笇鞛呺媹雼�. MDT鞚� 鞎� 13鞏� 欤� 氚滍枆 欤检嫕鞚� 瓿犽牑頃� 霑� 頋劃 鞓來枼鞚� 氙鸽頃╇媹雼�(<0.01%). 毵る弰 氤搓碃臧� 鞐嗢柎 瓯半灅 鞁Μ電� 於旊頃� 靾� 鞐嗢姷雼堧嫟.
Medtronic plc (MDT) 鈥� D茅claration d鈥檌niti茅 Formulaire 4. Le 28/07/2025, la soci茅t茅 a attribu茅 des actions 脿 Harry Skip Kiil, EVP et Pr茅sident Cardiovasculaire. La d茅claration ne montre aucune transaction sur le march茅 ouvert ; toutes les transactions portent le code 芦 A 禄 (attribution).
- Unit茅s d鈥檃ctions restreintes (RSUs) : 7 612 actions ordinaires, acquises 脿 100 % 脿 la troisi猫me ann茅e. La propri茅t茅 effective des actions ordinaires passe 脿 41 318.
- Unit茅s d鈥檃ctions de performance (PSUs) : Objectif de 19 028 actions (plage de 0 脿 38 056), conditionn茅 脿 des crit猫res de performance sur 3 ans se terminant le 28/04/2028.
- Options d鈥檃chat d鈥檃ctions : 53 671 options avec un prix d鈥檈xercice de 91,97 $, expirant le 28/07/2035 ; 25 % deviennent exer莽ables chaque ann茅e 脿 partir du 28/07/2026.
Apr猫s ces attributions, l鈥檌niti茅 d茅tient directement 41 318 actions ordinaires ainsi que 19 028 PSUs et 53 671 options. Ces r茅compenses repr茅sentent une compensation annuelle standard 脿 long terme visant 脿 aligner la direction avec les actionnaires et 脿 encourager la fid茅lisation. 脡tant donn茅 le nombre d鈥檃ctions en circulation d鈥檈nviron 1,3 milliard chez MDT, l鈥檌mpact dilutif est n茅gligeable (<0,01 %). Aucune vente n鈥檃 茅t茅 signal茅e, il est donc impossible d鈥檌nf茅rer le sentiment du march茅.
Medtronic plc (MDT) 鈥� Insider-Meldung Form 4. Am 28.07.2025 gew盲hrte das Unternehmen Aktienpr盲mien an Harry Skip Kiil, EVP & Pr盲sident Cardiovascular. Die Meldung zeigt keine offenen Markttransaktionen; alle Transaktionen sind mit dem Code 鈥濧鈥� (Zuteilung) gekennzeichnet.
- Restricted Stock Units (RSUs): 7.612 Stammaktien, die zu 100 % am dritten Jahrestag vesten. Das wirtschaftliche Eigentum an Stammaktien steigt auf 41.318.
- Performance Share Units (PSUs): Ziel von 19.028 Aktien (Spanne 0鈥�38.056), abh盲ngig von 3-Jahres-Leistungskennzahlen, die am 28.04.2028 enden.
- Aktienoptionen: 53.671 Optionen mit einem Aus眉bungspreis von 91,97$, Laufzeit bis 28.07.2035; 25 % werden j盲hrlich ab dem 28.07.2026 aus眉bbar.
Nach den Zuteilungen h盲lt der Insider direkt 41.318 Stammaktien sowie 19.028 PSUs und 53.671 Optionen. Die Pr盲mien stellen eine standardm盲脽ige j盲hrliche langfristige Anreizverg眉tung dar, die darauf abzielt, das Management mit den Aktion盲ren zu alignieren und die Bindung zu f枚rdern. Angesichts der ca. 1,3 Mrd. Aktien von MDT ist die Verw盲sserungswirkung unerheblich (<0,01 %). Es wurden keine Verk盲ufe gemeldet, daher l盲sst sich keine Handelsstimmung ableiten.
- Alignment of interests: Performance-based and time-vested awards encourage long-term value creation.
- No insider selling: Entire transaction consists of equity grants; no negative sell signal.
- Potential dilution: If all awards vest/exercise, 80,311 new shares could be issued, albeit immaterial relative to total shares.
Insights
TL;DR: Routine equity grant to MDT senior executive; negligible dilution and neutral fundamental impact.
The Form 4 discloses routine long-term incentive awards鈥擱SUs, PSUs and options鈥攖o EVP Harry Kiil. The option strike of $91.97 matches the market on grant date, so value creation depends on future price appreciation. PSUs add performance conditions, tying payout to company metrics through 2028. The total shares involved (< 0.07 % of equity) are too small to alter valuation or float dynamics. With no dispositions, the filing neither signals insider confidence nor concern. I classify the filing as neutral/not impactful for investors.
Medtronic plc (MDT) 鈥� Comunicazione interna Form 4. Il 28/07/2025 la societ脿 ha assegnato premi azionari a Harry Skip Kiil, EVP e Presidente Cardiovascolare. La comunicazione non evidenzia operazioni sul mercato aperto; tutte le transazioni sono classificate con il codice 鈥淎鈥� (assegnazione).
- Azioni vincolate (Restricted Stock Units): 7.612 azioni ordinarie, con maturazione completa al terzo anniversario. La propriet脿 effettiva delle azioni ordinarie sale a 41.318.
- Azioni a prestazione (Performance Share Units - PSU): Obiettivo di 19.028 azioni (intervallo 0鈥�38.056) subordinato al raggiungimento di metriche di performance triennali con scadenza 28/04/2028.
- Opzioni su azioni: 53.671 opzioni con prezzo di esercizio di 91,97$, in scadenza il 28/07/2035; il 25% diventa esercitabile ogni anno a partire dal 28/07/2026.
Dopo queste assegnazioni, l鈥檌nsider detiene direttamente 41.318 azioni ordinarie, oltre a 19.028 PSU e 53.671 opzioni. I premi rappresentano una normale forma di compenso incentivante a lungo termine, finalizzata ad allineare il management con gli azionisti e favorire la retention. Considerando il capitale sociale di MDT di circa 1,3 miliardi di azioni, l鈥檌mpatto diluitivo 猫 trascurabile (<0,01%). Non sono state riportate vendite, quindi non 猫 possibile dedurre il sentiment di trading.
Medtronic plc (MDT) 鈥� Presentaci贸n interna Formulario 4. El 28/07/2025 la empresa otorg贸 premios accionariales a Harry Skip Kiil, EVP y Presidente de Cardiovascular. La presentaci贸n no muestra operaciones en mercado abierto; todas las transacciones llevan el c贸digo 鈥淎鈥� (adjudicaci贸n).
- Unidades de acciones restringidas (RSUs): 7.612 acciones ordinarias, que se consolidan al 100% en el tercer aniversario. La propiedad efectiva de acciones ordinarias aumenta a 41.318.
- Unidades de acciones por desempe帽o (PSUs): Objetivo de 19.028 acciones (rango 0鈥�38.056) condicionado a m茅tricas de desempe帽o a 3 a帽os que concluyen el 28/04/2028.
- Opciones sobre acciones: 53.671 opciones con precio de ejercicio de $91,97, expiran el 28/07/2035; el 25% se vuelve ejercitable cada a帽o a partir del 28/07/2026.
Tras las concesiones, el insider posee directamente 41.318 acciones ordinarias, m谩s 19.028 PSUs y 53.671 opciones. Los premios representan una compensaci贸n est谩ndar anual a largo plazo destinada a alinear la gesti贸n con los accionistas y fomentar la retenci贸n. Dado que MDT tiene aproximadamente 1,3 mil millones de acciones en circulaci贸n, el impacto dilutivo es insignificante (<0.01%). No se reportaron ventas, por lo que no se puede inferir el sentimiento de negociaci贸n.
Medtronic plc (MDT) 鈥� 雮措秬鞛� Form 4 鞁犼碃. 2025雲� 7鞗� 28鞚� 須岇偓電� 鞁槇甏� 攵�氍� EVP 瓴� 靷灔鞚� Harry Skip Kiil鞐愱矊 欤检嫕 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 鞁犼碃靹滌棎電� 鞁滌灔 雮� 瓯半灅 鞐嗢潓鞚� 氇呾嫓霅橃柎 鞛堨溂氅�, 氇摖 瓯半灅電� 旖旊摐 鈥淎鈥�(靾橃棳)搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
- 鞝滍暅 欤检嫕 雼渼(RSUs): 7,612 氤错喌欤�, 3欤茧厔 旮半厫鞚检棎 100% 氩犾姢韺�. 氤挫湢 欤检嫕 靾橂姅 41,318欤茧 歃濌皜頃╇媹雼�.
- 靹标臣 欤检嫕 雼渼(PSUs): 氇╉憸 19,028欤� (0~38,056 氩旍渼), 3雲� 靹标臣 歆�響滌棎 霐半澕 2028雲� 4鞗� 28鞚检棎 斓滌 韽夑皜.
- 鞀ろ啞 鞓奠厴: 頄夓偓臧� 91.97雼煬鞚� 53,671欤�, 毵岅赴 2035雲� 7鞗� 28鞚�; 2026雲� 7鞗� 28鞚茧秬韯� 毵る厔 25%鞌� 頄夓偓 臧�電�.
鞚措矆 攵�鞐� 頉� 雮措秬鞛愲姅 歆侅爲 41,318欤� 氤错喌欤检檧 19,028 PSUs, 53,671 鞀ろ啞 鞓奠厴鞚� 氤挫湢頃橁矊 霅╇媹雼�. 鞚� 氤挫儊鞚� 瓴届榿歆勱臣 欤检＜ 臧� 鞚错暣毳� 毵烄稊瓿� 鞚胳灛 鞙犾毳� 鞛ル牑頃橁赴 鞙勴暅 響滌 鞐瓣皠 鞛リ赴 鞚胳劶韹半笇鞛呺媹雼�. MDT鞚� 鞎� 13鞏� 欤� 氚滍枆 欤检嫕鞚� 瓿犽牑頃� 霑� 頋劃 鞓來枼鞚� 氙鸽頃╇媹雼�(<0.01%). 毵る弰 氤搓碃臧� 鞐嗢柎 瓯半灅 鞁Μ電� 於旊頃� 靾� 鞐嗢姷雼堧嫟.
Medtronic plc (MDT) 鈥� D茅claration d鈥檌niti茅 Formulaire 4. Le 28/07/2025, la soci茅t茅 a attribu茅 des actions 脿 Harry Skip Kiil, EVP et Pr茅sident Cardiovasculaire. La d茅claration ne montre aucune transaction sur le march茅 ouvert ; toutes les transactions portent le code 芦 A 禄 (attribution).
- Unit茅s d鈥檃ctions restreintes (RSUs) : 7 612 actions ordinaires, acquises 脿 100 % 脿 la troisi猫me ann茅e. La propri茅t茅 effective des actions ordinaires passe 脿 41 318.
- Unit茅s d鈥檃ctions de performance (PSUs) : Objectif de 19 028 actions (plage de 0 脿 38 056), conditionn茅 脿 des crit猫res de performance sur 3 ans se terminant le 28/04/2028.
- Options d鈥檃chat d鈥檃ctions : 53 671 options avec un prix d鈥檈xercice de 91,97 $, expirant le 28/07/2035 ; 25 % deviennent exer莽ables chaque ann茅e 脿 partir du 28/07/2026.
Apr猫s ces attributions, l鈥檌niti茅 d茅tient directement 41 318 actions ordinaires ainsi que 19 028 PSUs et 53 671 options. Ces r茅compenses repr茅sentent une compensation annuelle standard 脿 long terme visant 脿 aligner la direction avec les actionnaires et 脿 encourager la fid茅lisation. 脡tant donn茅 le nombre d鈥檃ctions en circulation d鈥檈nviron 1,3 milliard chez MDT, l鈥檌mpact dilutif est n茅gligeable (<0,01 %). Aucune vente n鈥檃 茅t茅 signal茅e, il est donc impossible d鈥檌nf茅rer le sentiment du march茅.
Medtronic plc (MDT) 鈥� Insider-Meldung Form 4. Am 28.07.2025 gew盲hrte das Unternehmen Aktienpr盲mien an Harry Skip Kiil, EVP & Pr盲sident Cardiovascular. Die Meldung zeigt keine offenen Markttransaktionen; alle Transaktionen sind mit dem Code 鈥濧鈥� (Zuteilung) gekennzeichnet.
- Restricted Stock Units (RSUs): 7.612 Stammaktien, die zu 100 % am dritten Jahrestag vesten. Das wirtschaftliche Eigentum an Stammaktien steigt auf 41.318.
- Performance Share Units (PSUs): Ziel von 19.028 Aktien (Spanne 0鈥�38.056), abh盲ngig von 3-Jahres-Leistungskennzahlen, die am 28.04.2028 enden.
- Aktienoptionen: 53.671 Optionen mit einem Aus眉bungspreis von 91,97$, Laufzeit bis 28.07.2035; 25 % werden j盲hrlich ab dem 28.07.2026 aus眉bbar.
Nach den Zuteilungen h盲lt der Insider direkt 41.318 Stammaktien sowie 19.028 PSUs und 53.671 Optionen. Die Pr盲mien stellen eine standardm盲脽ige j盲hrliche langfristige Anreizverg眉tung dar, die darauf abzielt, das Management mit den Aktion盲ren zu alignieren und die Bindung zu f枚rdern. Angesichts der ca. 1,3 Mrd. Aktien von MDT ist die Verw盲sserungswirkung unerheblich (<0,01 %). Es wurden keine Verk盲ufe gemeldet, daher l盲sst sich keine Handelsstimmung ableiten.
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||||||||
| Exhibit Number | Exhibit Title | |||||||
99.1 | Press release of Carlisle Companies Incorporated dated July 30, 2025. | |||||||
| 104 | Cover page interactive data file (embedded within the inline XBRL document). | |||||||
| CARLISLE COMPANIES INCORPORATED | |||||||||||
| Date: | July 30, 2025 | By: | /s/ Kevin P. Zdimal | ||||||||
| Kevin P. Zdimal | |||||||||||
| Vice President and Chief Financial Officer | |||||||||||
Source:
FAQ
What did Medtronic (MDT) disclose in the latest Form 4?
How many Medtronic shares were granted to the executive?
What is the strike price and term of the new stock options?
When will the restricted stock units vest?
Is this insider transaction material to Medtronic investors?
